Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise

Molnupiravir led to a faster decrease in infectious virus among participants with early COVID-19

- PMLiVE

GCI Health opens new office in Brussels

Move expands agency's global public affairs offering

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

- PMLiVE

Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s

Country's Health Ministry also recommended extending gap between doses to 12 weeks

- PMLiVE

GSK, Vir halt enrolment of phase 3 COVID-19 antibody study

Move comes after recommendation from independent data and safety monitoring board

- PMLiVE

Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition

Five Prime's pipeline includes potentially first-in-class anti-FGFR2b antibody bemarituzumab

Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

Impetus Digital

CRM Design and Optimization for Life Science Organizations

John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical...

Impetus Digital

- PMLiVE

CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

The European Medicines Agency is also reviewing an application for the drug

- PMLiVE

MHRA to fast-track vaccines modified for new COVID-19 variants

Pfizer, Moderna and AstraZeneca are all working on modified vaccines

- PMLiVE

EMA begins rolling review process for Sputnik V COVID-19 vaccine

Late-stage trial results found vaccine gives 91.6% protection against COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links